Thomas Steyer’s Roivant Sciences ROIV Stock Holding History

Thomas Steyer’s Portfolio ROIV Stock Details ROIV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$506M	Buy	14,309,000 +4,634,000	+48%	+$137M	2.34%	13
2026 Q1	$268M	Buy	9,675,000 +9,638,000	+26,049%	+$248M	1.41%	24
2025 Q4	$803K	Hold	37,000	–	–	﹤0.01%	89
2025 Q3	$560K	Hold	37,000	–	–	﹤0.01%	88
2025 Q2	$417K	Hold	37,000	–	–	﹤0.01%	95
2025 Q1	$373K	Hold	37,000	–	–	﹤0.01%	100
2024 Q4	$438K	Hold	37,000	–	–	﹤0.01%	101
2024 Q3	$427K	Sell	37,000 -636,000	-95%	-$7.24M	﹤0.01%	110
2024 Q2	$7.11M	Sell	673,000 -225,600	-25%	-$2.47M	0.03%	87
2024 Q1	$9.47M	Sell	898,600 -6,437,400	-88%	-$69.4M	0.04%	93
2023 Q4	$82.4M	Buy	7,336,000 +3,482,600	+90%	+$33.9M	0.38%	50
2023 Q3	$45M	Buy	3,853,400 +1,498,400	+64%	+$16.9M	0.21%	60
2023 Q2	$23.7M	Buy	+2,355,000	New	+$21.1M	0.12%	76

Other funds holding ROIV

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

QVT Financial New York $1.7B AUM 173.77% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Thomas Steyer's ROIV Position: Q2 2026 in Review

Thomas Steyer increased its Roivant Sciences (ROIV) stake by 48% in Q2 2026, buying an estimated $137M and bringing the position to 14,309,000 shares worth $506M. The position accounts for 2.34% of the portfolio, ranked #13.

Thomas Steyer first reported a position in ROIV in Q2 2023 and has held it in 13 quarters since. 495 funds tracked by Wall St. Rank hold ROIV as of Q2 2026.

Thomas Steyer held 14,309,000 shares of Roivant Sciences worth $506M as of Q2 2026.
Thomas Steyer bought 4,634,000 Roivant Sciences shares in Q2 2026, an estimated $137M.
Roivant Sciences made up 2.34% of Thomas Steyer's portfolio in Q2 2026, its #13 holding.
Thomas Steyer first reported a position in Roivant Sciences in Q2 2023 and has held it in 13 quarters since.
495 funds tracked by Wall St. Rank held Roivant Sciences as of Q2 2026.

Based on Farallon Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.